CYP11A1 and melanoma: A variety of vitamin D3 and D2 derivatives were tested including classical forms, chemically generated low calcemic forms, and CYP11A1-derived non-calcemic or low calcemic variants, all of them showing anti-melanoma activities on cultured melanoma cells [51,63,188,285,410,411,439,441,443,449,461,483,484,487,489,533,569,588,593,594,595,596,597].